<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03087240</url>
  </required_header>
  <id_info>
    <org_study_id>S-130/2016</org_study_id>
    <nct_id>NCT03087240</nct_id>
  </id_info>
  <brief_title>Dental Prophylaxis and Rheumatoid Arthritis</brief_title>
  <acronym>PREPARA II</acronym>
  <official_title>Influence of Dental Prophylaxis on Disease Activity of Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the influence of dental prophylaxis on disease activity of Rheumatoid
      Arthritis. In addition to standard antirheumatic therapy, recently the question has been
      raised whether or not there is a supplementary beneficial effect due to professional teeth
      cleaning. So far just a few studies pursued this question, indicating that prophylaxis by
      dental professionals can alleviate the symptoms of Rheumatoid Arthritis. To further evaluate
      this question, in our study half of the participants will receive dental prophylaxis at their
      first visit, after 2 weeks and 3 months, while the other half will receive professional teeth
      cleaning after 3 months only.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Periodontitis (PA) and Rheumatoid Arthritis (RA) both rely on an over-regulated immune
      response, leading to inflammation in joints and periodontium. It is known, that both diseases
      have a reciprocal influence and that therapy of one disease may have beneficial effects on
      the course of the other.

      This study evaluates the influence of dental prophylaxis on disease activity of Rheumatoid
      Arthritis, in addition to standard antirheumatic therapy. Patients are being recruited from
      the Department of Rheumatology at the Heidelberg University Hospital. Patients being
      diagnosed with an active Rheumatoid Arthritis (DAS28-Score &gt; 3.2) will be included into the
      current study.

      The study follows a prospective, randomized, controlled study design with the participating
      dental and rheumatologic investigators being both blinded. The first visit (T0) includes the
      assessment of demographic and disease-related parameters, such as quality of life (HAQ -
      Health Assessment Questionnaire) and disease activity (DAS28 - Disease Activity Score 28) by
      a rheumatologist. Afterwards a dental investigator will determine the status of oral health
      with standard parameters (periodontal status (pocket depth, attachment level, Bleeding on
      Probing (BPI)) and dental status (DMFT - Decayed Missing Filled Teeth)). Subsequently
      patients are being randomized 1:1. The dental intervention is defined as a standardized
      dental prophylaxis according to the Heidelberg Therapeutic Scheme for Hygienization of the
      Oral Condition by means of professional teeth cleaning and motivational and demonstrational
      measures for implementing a sufficient oral hygiene.

      Group 1 (Test) contains patients being randomized for the dental intervention at first visit.
      Accordingly Group 2 (Control) contains patients not being randomized for the dental
      intervention. After 14 days (T1) patients in Group 1 undergo once again dental prophylaxis
      according the Heidelberg Therapeutic Scheme. The next follow-up is being executed after 3
      months (T2) by rheumatologic and dental investigators again. The primary outcome consists of
      the evaluation of the disease activity of the Rheumatoid Arthritis measured by the
      DAS28-Score between first visit (T0) and after 3 months (T2). Patients of Group 2 receive
      dental prophylaxis after 3 months due to ethical reasons (&quot;Wait &amp; Control Study Design&quot;). The
      final visit takes place after an additional 3 months (T3), in order to evaluate a possible
      long-term effect of the dental intervention.

      Furthermore the development of the bacterial microflora and inflammatory cytokine profile is
      being investigated. For this purpose, samples of supra- and subgingival plaque, gingival
      crevicular fluid and saliva at visits T0, T2 and T3 as well as stool samples at T0 and T2 are
      being collected. These will be analyzed qualitatively and quantitatively by molecular genetic
      methods.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2017</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Activity Score 28 (DAS28)</measure>
    <time_frame>baseline (T0) and three months (T2)</time_frame>
    <description>The Disease Activity Score 28 (DAS28) combines single measures into an overall, continuous measure of Rheumatoid Arthritis disease activity. The DAS28 includes a 28 tender joint count, a 28 swollen joint count, acute phase reactant and a general health assessment on a visual analog scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire (HAQ)</measure>
    <time_frame>baseline (T0) and three months (T2)</time_frame>
    <description>The Health Assessment Questionnaire (HAQ) is a comprehensive, validated, patient-oriented outcome assessment instrument. It includes the five dimensions disability, pain, medication effects, costs of care and mortality, which are then further subcategorized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiome and Inflammatory Cytokine Profile</measure>
    <time_frame>baseline (T0), three months (T2) and six months (T3)</time_frame>
    <description>The development of the bacterial microflora and inflammatory cytokine profile is being analyzed qualitatively and quantitatively by molecular genetic methods. Samples of supra- and subgingival plaque, gingival crevicular fluid and saliva are being collected at T0, T2 and T3, stool samples are being collected at T0 and T2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Steroid Dose</measure>
    <time_frame>baseline (T0), three months (T2) and six months (T3)</time_frame>
    <description>The cumulative steroid dose is being compared between Group 1 (Test) and Group 2 (Control).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Periodontitis</condition>
  <condition>Gingivitis</condition>
  <condition>Dental Prophylaxis</condition>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dental Prophylaxis at fist visit (T0), after 2 weeks (T1) and after 3 months (T2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Wait &amp; Control Study Design: Dental Prophylaxis after 3 months (T2) only</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Dental Prophylaxis</intervention_name>
    <description>Prevention and treatment of periodontal diseases by cleaning of the teeth in the dental office using the procedures of dental scaling and dental polishing. The treatment includes plaque detection, removal of supra- and subgingival plaque and calculus, as well as motivation and demonstration for establishing a sufficient oral hygiene.</description>
    <arm_group_label>Test</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>Professional Teeth Cleaning</other_name>
    <other_name>Dental Scaling</other_name>
    <other_name>Dental Polishing</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed consent form

          -  Diagnosis of an active Rheumatoid Arthritis (DAS28 &gt; 3.2) by a rheumatologist

          -  Gingiva Bleeding Index (GBI) &gt; 10%, Plaque Control Record (PCR) &gt; 30% (indication for
             Dental Prophylaxis following the Heidelberg Therapeutic Scheme)

        Exclusion Criteria:

          -  Generalized Severe Chronic Periodontitis

          -  Periodontal treatment within the last 6 months

          -  Dental Prophylaxis within the last 6 months

          -  Dental Prophylaxis being contraindicated due to dental or other reasons

          -  Antibiotic treatment within the last 3 months (excluding intake of antibiotic
             prophylaxis)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana Wolff, Prof. Dr. med. dent.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Heidelberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diana Wolff, Prof. Dr. med. dent.</last_name>
    <phone>+49 (0)6221-56-6589</phone>
    <email>diana.wolff@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kyrill Schoilew, Dr. med. dent.</last_name>
    <email>kyrill.schoilew@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Wolff, Prof. Dr. med. dent.</last_name>
      <phone>+49 (0)6221-56-6589</phone>
      <email>diana.wolff@med.uni-heidelberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Kyrill Schoilew, Dr. med. dent.</last_name>
      <email>kyrill.schoilew@med.uni-heidelberg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Diana Wolff, Prof. Dr. med. dent.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bj√∂rn Wolff, Dr. rer. nat.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Felten, Dr. med. dent.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Niko Bender, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kyrill Schoilew, Dr. med. dent.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Janssen KM, Vissink A, de Smit MJ, Westra J, Brouwer E. Lessons to be learned from periodontitis. Curr Opin Rheumatol. 2013 Mar;25(2):241-7. doi: 10.1097/BOR.0b013e32835d833d. Review.</citation>
    <PMID>23370377</PMID>
  </reference>
  <reference>
    <citation>Ortiz P, Bissada NF, Palomo L, Han YW, Al-Zahrani MS, Panneerselvam A, Askari A. Periodontal therapy reduces the severity of active rheumatoid arthritis in patients treated with or without tumor necrosis factor inhibitors. J Periodontol. 2009 Apr;80(4):535-40. doi: 10.1902/jop.2009.080447.</citation>
    <PMID>19335072</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2017</study_first_submitted>
  <study_first_submitted_qc>March 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2017</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Diana Wolff</investigator_full_name>
    <investigator_title>Deputy Medical Director, Department of Conservative Dentistry</investigator_title>
  </responsible_party>
  <keyword>Disease Activity Score 28 (DAS28)</keyword>
  <keyword>Health Assessment Questionnaire (HAQ)</keyword>
  <keyword>Dental Scaling</keyword>
  <keyword>Dental Polishing</keyword>
  <keyword>Oral Health</keyword>
  <keyword>Gingival Crevicular Fluid</keyword>
  <keyword>Inflammatory Cytokine Profile</keyword>
  <keyword>Biofilm</keyword>
  <keyword>Oral Microbiome</keyword>
  <keyword>Intestinal Microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Periodontitis</mesh_term>
    <mesh_term>Gingivitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

